TNFR2

BioInvent's CMO comments on phase I/IIa data with BI-1808

BioInvent's Phase I/IIa study with the first-in-class anti-TNFR2 antibody BI-1808 in advanced cancer has yielded positive results. The strong interim safety data paves the way...